ImmuneOncia Therapeutics Enters into Collaboration with Lonza to Manufacture Danburstotug for Immuno-Oncology
Tuesday, March 31, 2026
ImmuneOncia Therapeutics has entered into a manufacturing agreement with Lonza to support the late-stage clinical supply of its investigational immuno-oncology therapy, Danburstotug (IMC-001).
Danburstotug is a fully human monoclonal antibody developed as an immune checkpoint inhibitor targeting PD-L1. It is currently being studied for the treatment of relapsed or refractory NK/T-cell lymphoma, a rare and aggressive cancer with limited treatment options.
Under the agreement, Lonza will deliver development and clinical manufacturing services for both the drug substance and drug product. The drug substance will be produced at Lonza’s facility in Slough, UK, while drug product development and manufacturing will take place at its sites in Basel and Stein, Switzerland.
The collaboration allows ImmuneOncia to use Lonza’s integrated development and manufacturing network, along with its regulatory experience, to support the advancement of Danburstotug through late-stage clinical development and prepare for potential commercialisation.
ImmuneOncia aims to pursue early approval for Danburstotug in NK/T-cell lymphoma, with the partnership expected to strengthen its position for future global licensing and market expansion. Lonza’s end-to-end capabilities are intended to help streamline the development process and support the transition towards bringing the therapy to international markets.
Source: lonza.com
